证券代码：002001 证券简称：新和成 公告编号：2025-052 浙江新和成股份有限公司 第九届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十六次会议 于 2025 年 12 月 5 日以电子邮件方式发出会议通知，于 2025 年 12 月 10 日以现 场结合通讯表决方式召开。应参加表决董事十一名，实际参加表决董事十一名。 公司监事和高级管理人员列席了会议。符合《公司法》和《公司章程》的规定。 会议经表决形成决议如下： 一、会议以 11 票同意，0 票反对，0 票弃权审议通过《关于修订<公司章程> 的议案》；该议案尚需提交股东大会审议。 为进一步规范公司运作，提高科学治理水平，保护投资者合法权益，根据《公 司法》（2024 年 7 月 1 日起施行）及中国证监会发布的《关于新<公司法>配套制 度规则实施相关过渡期安排》《上市公司章程指引(2025 年修订)》等相关法律法 规的规定，结合公司实际情况，对现行《公司章程》进行修订。本次修订后，公 司将不再设置监事会，《公司 ...

5、公司实施本员工持股计划的目的在于：基于对公司未来发展前景的信心 和内在价值的认可，弘扬新和成"创富、均衡、永续"的经营哲学，落实新和成 "创造财富，成就员工，造福社会"的企业宗旨。让优秀人才和贡献者分享公司 成长成果，体现"以贡献者为本"的分配机制，推动员工与企业共创、共担、共 1、公司不存在《指导意见》《1号指引》等有关法律、行政法规、规章、规 范性文件规定的禁止实施员工持股计划的情形。 2、公司第五期员工持股计划的内容符合《公司法》《证券法》《指导意见》 《1号指引》等有关法律、行政法规、规章、规范性文件以及《公司章程》的规 定，计划推出前已征求员工意见，不存在损害公司及全体股东利益的情形。 3、董事会薪酬与考核委员会对第五期员工持股计划名单进行了核实，认为 公司第五期员工持股计划拟定的持有人均符合《指导意见》《1号指引》等有关 法律、行政法规、规章、规范性文件规定的持有人条件，符合第五期员工持股计 划规定的持有人范围，其作为公司本员工持股计划持有人的主体资格合法、有效。 4、第五期员工持股计划不存在摊派、强行分配等方式强制员工参与第五期 员工持股计划的情形，亦不存在公司向第五期员工持股计划持有人提供 ...

Core Insights - The Chinese chemical industry is at a critical stage of cyclical bottoming and deepening industrial upgrades, characterized by demand differentiation, supply structure optimization, cost pressure alleviation, and clear policy guidance [1][4] Overall Overview - The A-share chemical sector has over 431 listed companies, ranking fourth among all industries in terms of quantity and influence [1] - Chemical products dominate the sector, accounting for over 40% in various dimensions such as quantity, market value, revenue, and profit, serving as the core engine of industry development [1] - The industry structure shows significant differentiation, with plastics, agricultural chemicals, and chemical raw materials as important supports, while sectors like chemical fibers and rubber are relatively smaller [1] Market Performance - The chemical industry faced overall pressure from 2024 to August 2025, with chemical prices remaining low and valuations at historical lows, leading to stock performance lagging behind the broader market [2] - Despite the overall market pressure, some companies like Zhengdan Co. and Annuoqi achieved significant market value increases through emerging sector layouts, while traditional companies generally faced market value shrinkage [2] Operating Conditions - The revenue of chemical listed companies showed resilience, with a year-on-year growth of 3.23% in 2024, although net profit attributable to shareholders decreased by 8.09% [2] - There is a notable divergence in operational capabilities, with leading companies optimizing asset and accounts management through technological barriers and scale effects [2] - The overall asset-liability ratio has increased, reflecting a balance between investment in industrial upgrades and cyclical responses [2] Technological Innovation - R&D investment in chemical companies has been increasing, with R&D intensity rising to 3.08%, and resources concentrating on high-end sectors and leading companies [3] - The proportion of R&D personnel is steadily increasing, with the chemical products sector having the highest density of R&D talent, indicating a trend towards technology-driven transformation [3] International Development - The proportion of overseas revenue for chemical listed companies rebounded to 21.63% in 2024, with strong performance in chemical products and agricultural chemicals in international markets [3] - Although foreign ownership has generally decreased, it is increasingly concentrated in high-end technology companies, reflecting international capital's recognition of China's chemical industry's high-end transformation [3] Policy Guidance - The government continues to promote green, high-end, and intelligent development in the chemical industry, encouraging companies to cluster in chemical parks and enhance industrial chain collaboration [3] - Restrictive policies are accelerating the exit of backward production capacity, optimizing the industrial layout, and creating a more regulated environment for high-quality development [3] Case Studies - Wanhua Chemical has built a scale moat through integrated layout and global expansion, while New Hecheng has achieved counter-cyclical growth through technological barriers and specialization [3] - The case of Aowei New Materials highlights the market's concern over the mismatch between valuation and fundamentals, emphasizing the importance of profit realization for valuation support [3]

证券日报网讯 12月8日，新和成（002001）在互动平台回答投资者提问时表示，浙江爱生系本公司控股 股东新和成控股集团有限公司控制的另一家上市公司"福元医药（601089）"（股票代码601089）的子公 司。 ...

截至12月8日收盘，青蒿素概念下跌0.51%，位居概念板块跌幅榜前列，板块内，德龙汇能、百花医 药、新和成等跌幅居前。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 共封装光学(CPO) | 4.72 | 天津自贸区 | -0.99 | | F5G概念 | 4.30 | 草甘膦 | -0.86 | | 光纤概念 | 3.67 | 青蒿素 | -0.51 | | 铜缆高速连接 | 3.57 | 煤炭概念 | -0.51 | | 福建自贸区 | 3.44 | 高股息精选 | -0.38 | | PET铜箔 | 3.02 | 超级品牌 | -0.34 | | 海南自贸区 | 3.00 | 金属锌 | -0.32 | | WiFi 6 | 3.00 | 大豆 | -0.31 | | 光刻机 | 3.00 | 啤酒概念 | -0.31 | | 海峡两岸 | 2.98 | 共享单车 | -0.29 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.62亿元，其中，5股获主力资金净流出，净流出 资金居首的是德龙汇能， ...

Group 1 - The core viewpoint of the news is that the anti-dumping duties on polyphenylene sulfide (PPS) are being maintained and adjusted to protect domestic industries from foreign competition, particularly from Japan and the United States [2][7] - The anti-dumping tax rates for different companies range from 23.3% to 220.9%, with Japanese companies facing specific rates, the highest being 34.5% for Sumitomo Bakelite, while U.S. companies have the highest rates reaching up to 220.9% [2][4] - The demand for PPS is increasing significantly in China due to the growth of the automotive industry and emerging sectors like robotics, making it a crucial product for domestic supply chains [5][7] Group 2 - Japan has a strong presence in the PPS market, with several companies having high production capacities, while Chinese companies like Zhejiang Xinheng are emerging as leaders in the domestic market [4] - PPS is characterized by its high-temperature resistance, corrosion resistance, and excellent mechanical properties, making it suitable for applications in automotive electronics and robotics [5] - The Chinese government is implementing comprehensive countermeasures against Japan, indicating that the anti-dumping duties on PPS are likely to continue as part of a broader strategy to protect domestic industries [9]

证券之星消息，12月5日，医疗健康（980016）指数报收于6283.04点，涨0.48%，成交161.75亿元，换手 率0.61%。当日该指数成份股中，上涨的有32家，新和成以2.15%的涨幅领涨，下跌的有18家，信立泰以 2.12%的跌幅领跌。 医疗健康（980016）指数十大成份股详情如下： | 医疗健康指数 十大成份股 | | --- | | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sh603259 | 药明康德 | 13.66% | 90.40 | 0.90% | | 2697.32 | 医药生物 | | sh600276 | 恒瑞医药 | 11.00% | 61.62 | 0.60% | | 4089.84 | 医药生物 | | sz300760 | 迈瑞医疗 | 7.57% | 202.39 | 1.20% | | 2453.86 | 医药生物 | | sh688271 | 联影医疗 | 4.27% | 130.61 | 1.35% ...

Core Insights - The article highlights the achievements and future direction of the private economy in Weifang during the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan" Group 1: Economic Performance - Weifang's private economy has over 1.464 million market entities, accounting for 10.2% of the province, contributing over 80% of the city's investment, tax revenue, and imports/exports, with 99.2% of market entities being private, and the private economy accounting for 63% of GDP [1][2] Group 2: Industrial Strength - Key private enterprises such as Hongrun, Goer, and Haomai are rapidly growing, with over 95% of the 1,459 manufacturing champions and specialized small giants being private; Weifang has 5 companies in the top 500 private enterprises in China, ranking 3rd in the province [2] Group 3: Technological Innovation - The city has over 2,100 high-tech private enterprises and 3,600 technology-based SMEs, with significant innovations leading to national and provincial awards in technology advancement [2] Group 4: Social Contributions - Private enterprises play a crucial role in job creation, providing over 90% of employment opportunities in the city, contributing to a win-win situation for businesses, local revenue, and public benefit [3] Group 5: Government Support - Weifang government emphasizes the development of the private economy through various supportive measures, including optimizing the policy environment, enhancing industrial ecosystems, improving service quality, and fostering a business-friendly atmosphere [4] Group 6: Future Outlook - Looking ahead to the "15th Five-Year Plan," Weifang aims to further support the healthy and high-quality development of the private economy, ensuring that private enterprises can thrive and grow [5]

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]

Group 1 - The Artemisinin concept index rose by 0.57%, ranking 6th among concept sectors, with six stocks increasing in value, including Delong Huineng, Haizheng Pharmaceutical, and China Resources Double Crane, which rose by 4.38%, 2.49%, and 0.75% respectively [1] - The stocks with the largest declines included Baihua Pharmaceutical, Rundu Co., and Fosun Pharmaceutical, which fell by 2.20%, 0.50%, and 0.15% respectively [1] Group 2 - The main capital flow analysis indicates that the Artemisinin concept sector experienced a net outflow of 73 million yuan, with three stocks receiving net inflows, led by Haizheng Pharmaceutical with a net inflow of 2.9933 million yuan [2] - Other stocks with notable net inflows include Fosun Pharmaceutical and Kunming Pharmaceutical Group, with net inflows of 1.7788 million yuan and 1.4040 million yuan respectively [2] Group 3 - In terms of capital inflow ratios, Kunming Pharmaceutical Group, Haizheng Pharmaceutical, and Fosun Pharmaceutical had the highest net inflow rates at 3.59%, 1.88%, and 0.82% respectively [3] - The capital flow data for the Artemisinin concept shows that Haizheng Pharmaceutical had a daily increase of 2.49% with a turnover rate of 1.25% and a net inflow of 2.9933 million yuan [3] - Conversely, stocks like Rundu Co. and Zhejiang Medicine experienced negative net inflows of -2.35 million yuan and -3.5082 million yuan respectively, with net inflow rates of -4.49% and -5.28% [4]